# SLC34A2

Source: https://onco.cc/targets/slc34a2/  
OnCo record `slc34a2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.

## Summary

Involved in actively transporting phosphate into cells via Na(+) cotransport.

Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.15, literature 0.96, genetic association 0.48, somatic mutation 0.86, animal model 0.28). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Colorectal Adenocarcinoma, Lung Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: solute carrier family 34 member 2; Sodium-dependent phosphate transport protein 2B; NAPI-3B; NaPi-2b; NPTIIb; NaPi2b; NAPI-IIb
- Tags: cancer-genes-wave
- Symbol: SLC34A2
- Class: oncogene
- Biology: Involved in actively transporting phosphate into cells via Na(+) cotransport. Location: Apical cell membrane (UniProt). Locus 4p15.2 (HGNC).
- Where found: Lung cancer: Open Targets association 0.60 with lung cancer (MONDO_0008903); Colorectal cancer: IntOGen driver in 1 cohort (COADREAD); Non-small-cell lung cancer: Open Targets association 0.57 with non-small cell lung carcinoma (MONDO_0005233); IntOGen driver in 1 cohort (LUAD); Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.15; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11020: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11020
- UniProt O95436: https://www.uniprot.org/uniprotkb/O95436/entry
- NCBI Gene 10568: https://www.ncbi.nlm.nih.gov/gene/10568
- Ensembl ENSG00000157765: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157765

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/slc34a2.json